Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Lenacapavir, a twice-yearly injectable, is shown to be more effective than Truvada in preventing HIV in recent clinical trials.
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
Gilead's lenacapavir shows exceptional efficacy in preventing HIV and is a potential game-changer in the global fight against AIDS.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Gilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Lenacapavir, a twice-yearly injectable, is shown to be more effective than Truvada in preventing HIV in recent clinical trials.
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
Gilead's lenacapavir shows exceptional efficacy in preventing HIV and is a potential game-changer in the global fight against AIDS.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Gilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.